Irritable bowel syndrome or functional dyspepsia are present if abdominal pain or discomfort is present over a period of 12 weeks within the last 12 months, which is triggered by food intake (functional dyspepsia) or is relieved by bowel movements (irritable bowel syndrome). This also leads to changes in stool frequency and consistency, although there are no structural or biochemical changes that could explain these symptoms. Similar to inflammatory bowel disease, the incidence of irritable bowel syndrome has been steadily increasing in recent years. More women than men are affected, usually at a young age. The disease often begins with a severe intestinal infection and is accompanied by a disturbance of the intestinal microbiota.
In collaboration with Loha for Life, the research group led by Ao. Univ.-Prof. Dr. Gasche discovered endoscopically visible biofilms in the intestines of patients with irritable bowel syndrome. These biofilms are an expression of a serious disturbance of the intestinal microbiota and are often the result of repeated antibiotic intake. Modern therapeutic approaches have since been directed against these severe microbiological changes in the intestinal microbiome and include endoscopic cleansing procedures (Bioflush) and fecal matter transplantation (FMT). Further antibiotic therapy is usually not recommended.
For patients, transabdominal bowel sonography is the best test for the initial clarification of digestive complaints. Both the small and large intestine can be examined for structural and functional changes. Endoscopic examinations are necessary in older patients to rule out neoplastic disease of the colon. Capsule endoscopy can be used to detect biofilms or other diseases of the small intestine. Please always bring all previous findings to your first appointment at Loha for Life.
